Get the Stockscreener App
21.38
6.29%
-1.435
Pre-market:
19.67
-1.705
-7.98%
Longboard Pharmaceuticals Inc stock is currently priced at $21.38, with a 24-hour trading volume of 481.26K.
It has seen a -6.29% decreased in the last 24 hours and a +17.96% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $22.48 pivot point. If it approaches the $20.78 support level, significant changes may occur.
Previous Close:
$22.81
Open:
$23.5
24h Volume:
481.26K
Market Cap:
$831.02M
Revenue:
-
Net Income/Loss:
$-54.42M
P/E Ratio:
-8.3781
EPS:
-2.5513
Net Cash Flow:
$-50.87M
1W Performance:
+8.39%
1M Performance:
+17.96%
6M Performance:
+287.23%
1Y Performance:
+159.09%
1D Range:
$21.07
$23.95
52W Range:
$3.60
$28.15
Longboard Pharmaceuticals Inc Stock (LBPH) Company Profile
Name
Longboard Pharmaceuticals Inc
Sector
Industry
Phone
619 592 9775
Address
6154 Nancy Ridge Drive, San Diego
Longboard Pharmaceuticals Inc Stock (LBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-27-23 | Initiated | B. Riley Securities | Buy |
| Apr-07-21 | Initiated | Evercore ISI | Outperform |
| Apr-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-21 | Initiated | Citigroup | Buy |
| Apr-06-21 | Initiated | Guggenheim | Buy |
View All
Longboard Pharmaceuticals Inc Stock (LBPH) Latest News
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher
The Motley Fool
Cantor Fitzgerald Maintains Overweight Rating for Longboard Pharmaceuticals: Here's What You Need To Know
Benzinga
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
MarketWatch
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
Zacks Investment Research
Jim Cramer: This Energy Firm Has 'Good Growth, Good Yield' But As For IonQ? Ixnay
Benzinga
Longboard Pharmaceuticals Inc Stock (LBPH) Financials Data
Longboard Pharmaceuticals Inc (LBPH) Net Income 2024
LBPH net income (TTM) was -$54.42 million for the quarter ending December 31, 2023, a -23.84% decrease year-over-year.
Longboard Pharmaceuticals Inc (LBPH) Cash Flow 2024
LBPH recorded a free cash flow (TTM) of -$50.87 million for the quarter ending December 31, 2023, a -33.64% decrease year-over-year.
Longboard Pharmaceuticals Inc (LBPH) Earnings per Share 2024
LBPH earnings per share (TTM) was -$2.3813 for the quarter ending December 31, 2023, a +7.40% growth year-over-year.
About Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.
1.62%
0.15%
Cap:
|
Volume (24h):